Virbac USA veterinary site

Evidence

Explore case studies and scientific evidence about STELFONTA® (tigilanol tiglate injection):

Case studies

Explore our interactive case studies and see how STELFONTA® has delivered results in tumors across different locations in different breeds of dogs.

Click the images to enlarge and see each case.

TAP A LOCATION

TAP A LOCATION

Select a case

Breed :
Age :
Tumor :

Case summary

Dog weight : kg
Tumor volume : cm3
Doses received :
Complete response achieved

Case notes

Case notes

Case notes

Case notes

Case notes

Remember

- It is vital that pre- and post-treatment medications must be given to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation.
- Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with the associated swelling, bruising and pain; these wounds are expected to heal.

Publications and presentations

Check in for the latest STELFONTA® evidence and clinical updates on MCT management in dogs.

IMPORTANT SAFETY INFORMATION

FOR VETERINARIANS
Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or view the Product Insert.

 

FOR PET OWNERS
Wear disposable gloves when cleaning the treated tumor site to avoid contact with any residual drug. Thoroughly wash your skin that comes in contact with the treated tumor site, wound, or wound discharge. Ensure your dog receives their prescribed medications to decrease the potential for severe, life-threatening adverse reactions. Monitor your dog during the healing process and contact your veterinarian if you notice excessive pain, lameness, tiredness, refusal to eat for more than one day, repeated vomiting or diarrhea, trouble breathing, changes to the treated tumor site (including increased or excessive swelling and bruising, extensive wound formation, increased irritation) or any other symptoms that concern you. For full prescribing information, contact Virbac at 1-800-338-3659 or view the Product Insert.

Success Stories

Discover what the STELFONTA® treatment journey has been like for pet owners